Lixte Biotechnology Holdings, Inc.
LIXT
$4.86
-$0.01-0.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.61M | 2.85M | 3.14M | 3.41M | 3.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.31M | 3.57M | 3.99M | 4.03M | 4.69M |
| Operating Income | -3.31M | -3.57M | -3.99M | -4.03M | -4.69M |
| Income Before Tax | -3.32M | -3.59M | -4.00M | -4.03M | -4.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.32 | -3.59 | -4.00 | -4.03 | -4.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.32M | -3.59M | -4.00M | -4.03M | -4.69M |
| EBIT | -3.31M | -3.57M | -3.99M | -4.03M | -4.69M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.45 | -1.59 | -1.78 | -1.83 | -2.38 |
| Normalized Basic EPS | -0.91 | -1.00 | -1.11 | -1.14 | -1.49 |
| EPS Diluted | -1.45 | -1.59 | -1.78 | -1.83 | -2.38 |
| Normalized Diluted EPS | -0.91 | -1.00 | -1.11 | -1.14 | -1.49 |
| Average Basic Shares Outstanding | 9.22M | 9.00M | 9.00M | 8.83M | 8.24M |
| Average Diluted Shares Outstanding | 9.22M | 9.00M | 9.00M | 8.83M | 8.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |